Publications

Detailed Information

Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome

DC Field Value Language
dc.contributor.authorLee, S. H.-
dc.contributor.authorYoo, K. H.-
dc.contributor.authorSung, K. W.-
dc.contributor.authorKoo, H. H.-
dc.contributor.authorKwon, M. M.-
dc.contributor.authorPark, B-K-
dc.contributor.authorPark, J. A.-
dc.contributor.authorSeo, J. J.-
dc.contributor.authorShin, H. Y.-
dc.contributor.authorAhn, H. S.-
dc.contributor.authorKang, H. J.-
dc.contributor.authorIm, H. J.-
dc.contributor.authorKim, Y. Y.-
dc.contributor.authorPark, H. J.-
dc.contributor.authorKwon, Y. J.-
dc.date.accessioned2012-06-12T04:53:21Z-
dc.date.available2012-06-12T04:53:21Z-
dc.date.issued2010-08-
dc.identifier.citationBONE MARROW TRANSPLANTATION; Vol.45 8; 1287-1293ko_KR
dc.identifier.issn0268-3369-
dc.identifier.urihttps://hdl.handle.net/10371/77001-
dc.description.abstractFour hundred and sixty-seven hematopoietic stem cell transplantations (HSCTs) (217 autologous and 250 allogeneic HSCT) were performed in 374 children at four pediatric HSCT centers in Korea from January 2005 to December 2007. Among 467 transplants, veno-occlusive disease (VOD) developed in 72 transplants (15.4%) at a median of 10 days after HSCT. Multivariate analysis showed that BU or TBI-containing regimen (P = 0.002), VOD prophylaxis without lipo-prostaglandin E1 (PGE1) (P = 0.012), number of previous HSCT (P = 0.014), and pretransplant serum ferritin (P = 0.018) were independent risk factors for developing VOD. Mean serum ferritin levels were significantly higher in HSCT with VOD (2109.6 +/- 2842.5 ng/ml) than in HSCT without VOD (1315.9 +/- 1094.4 ng/ml) (P < 0.001). The relative risk of death within 100 days of HSCT in transplants with VOD compared with transplants without VOD was 3.39 (confidence interval: 1.78-6.45). Our results suggest that lipo-PGE1 might have a protective effect against the development of VOD, and pretransplant serum ferritin could act as a risk factor for VOD. A larger prospective study is needed to confirm a possible role of lipo-PGE1 and iron chelation therapy in reducing the incidence of VOD.ko_KR
dc.language.isoenko_KR
dc.publisherNATURE PUBLISHING GROUPko_KR
dc.subjectveno-occlusive diseaseko_KR
dc.subjectlipid microspheres-containing prostaglandin E1ko_KR
dc.subjectferritinko_KR
dc.subjectprophylaxisko_KR
dc.subjecthematopoietic stem cell transplantationko_KR
dc.titleHepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcomeko_KR
dc.typeArticleko_KR
dc.identifier.doi10.1038/bmt.2009.349-
dc.citation.journaltitleBONE MARROW TRANSPLANTATION-
dc.description.citedreferenceCutting R, 2008, BRIT J HAEMATOL, V143, P748, DOI 10.1111/j.1365-2141.2008.07399.x-
dc.description.citedreferenceCacchione A, 2008, BONE MARROW TRANSPL, V42, P449, DOI 10.1038/bmt.2008.186-
dc.description.citedreferenceQureshi A, 2008, PEDIATR BLOOD CANCER, V50, P831, DOI 10.1002/pbc.21425-
dc.description.citedreferenceJastaniah W, 2008, PEDIATR BLOOD CANCER, V50, P319, DOI 10.1002/pbe.21260-
dc.description.citedreferenceDignan F, 2007, BONE MARROW TRANSPL, V40, P79, DOI 10.1038/sj.bmt.1705696-
dc.description.citedreferenceArmand P, 2007, BLOOD, V109, P4586, DOI 10.1182/blood-2006-10-054924-
dc.description.citedreferenceCorbacioglu S, 2006, BONE MARROW TRANSPL, V38, P547, DOI 10.1038/sj.bmt.1705485-
dc.description.citedreferenceSong JS, 2006, J KOREAN MED SCI, V21, P897-
dc.description.citedreferenceCesaro S, 2005, HAEMATOL-HEMATOL J, V90, P1396-
dc.description.citedreferenceBeelen DW, 2005, BONE MARROW TRANSPL, V35, P233, DOI 10.1038/sj.bmt.1704784-
dc.description.citedreferenceEvens AM, 2004, BONE MARROW TRANSPL, V34, P561, DOI 10.1038/sj.bmt.1704591-
dc.description.citedreferenceChalandon Y, 2004, BIOL BLOOD MARROW TR, V10, P347, DOI 10.1016/j.bbmt.2004.01.002-
dc.description.citedreferenceWadleigh M, 2003, BLOOD, V102, P1578, DOI 10.1182/blood-2003-01-0255-
dc.description.citedreferenceBarker CC, 2003, BONE MARROW TRANSPL, V32, P79, DOI 10.1038/sj.bmt.1704069-
dc.description.citedreferenceForrest DL, 2003, BONE MARROW TRANSPL, V31, P1143, DOI 10.1038/sj.bmt.1704087-
dc.description.citedreferenceSimon M, 2001, BONE MARROW TRANSPL, V27, P627-
dc.description.citedreferenceValteau-Couanet D, 2000, BONE MARROW TRANSPL, V25, P937-
dc.description.citedreferenceGirinsky T, 2000, J CLIN ONCOL, V18, P981-
dc.description.citedreferenceMORADO M, 2000, HEMATOLOGY, V4, P505-
dc.description.citedreferenceToh HC, 1999, BONE MARROW TRANSPL, V24, P891-
dc.description.citedreferenceHasegawa S, 1998, BONE MARROW TRANSPL, V22, P1191-
dc.description.citedreferenceCarreras E, 1998, BLOOD, V92, P3599-
dc.description.citedreferenceOlivieri NF, 1998, NEW ENGL J MED, V339, P417-
dc.description.citedreferenceStyler MJ, 1996, BONE MARROW TRANSPL, V18, P171-
dc.description.citedreferenceOLIVIERI NF, 1994, NEW ENGL J MED, V331, P574-
dc.description.citedreferenceBEARMAN SI, 1993, J CLIN ONCOL, V11, P1729-
dc.description.citedreferenceBEARMAN SI, 1993, BRIT J HAEMATOL, V84, P724-
dc.description.citedreferenceMCDONALD GB, 1993, ANN INTERN MED, V118, P255-
dc.description.citedreferenceRADICH JP, 1993, J CLIN ONCOL, V11, P304-
dc.description.citedreferenceSHULMAN HM, 1992, BONE MARROW TRANSPL, V10, P197-
dc.description.citedreferenceMERESSE V, 1992, BONE MARROW TRANSPL, V10, P135-
dc.description.citedreferenceATTAL M, 1992, BLOOD, V79, P2834-
dc.description.citedreferenceMARSAVILA L, 1991, EUR J HAEMATOL, V47, P346-
dc.description.citedreferenceOZKAYNAK MF, 1991, BONE MARROW TRANSPL, V7, P467-
dc.description.citedreferenceMIZUSHIMA Y, 1990, PROSTAG LEUKOTR ESS, V41, P269-
dc.description.citedreferenceBEARMAN SI, 1990, BONE MARROW TRANSPL, V5, P407-
dc.description.citedreferenceGLUCKMAN E, 1990, BRIT J HAEMATOL, V74, P277-
dc.description.citedreferenceCOSSET JM, 1989, RADIOTHER ONCOL, V15, P151-
dc.description.citedreferenceGROCHOW LB, 1989, CANCER CHEMOTH PHARM, V25, P55-
dc.description.citedreferenceBRUGIERES L, 1988, BONE MARROW TRANSPL, V3, P53-
dc.description.citedreferenceSIM AK, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1206-
dc.description.citedreferenceOTOMO S, 1985, DRUG EXP CLIN RES, V11, P627-
dc.description.citedreferenceMIZUSHIMA Y, 1983, J PHARM PHARMACOL, V35, P666-
dc.description.citedreferencePIPER PJ, 1970, NATURE, V225, P600-
dc.description.tc3-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share